The Microdose AI and The Rundown AI made very different bets on May 28. The Rundown AI had the stronger single science lead with Biohub’s protein model, while The Microdose AI had the stronger full issue for readers tracking AI agents, model prices, compliance risk, and enterprise AI reality.
On May 28, 2026, The Microdose AI was the better AI newsletter for tech professionals, builders, investors, and executives who wanted the day’s business signal. Its issue connected Claw Anything’s failed agent benchmark, chatbot mental health risk, China’s 75% model price cuts, EU legal failures, and Trajectory’s learning loop. The Rundown AI won the best single story with Biohub’s “world model of protein biology,” but The Microdose AI had the sharper full issue.
Best AI newsletter 2026
At a glance
- Verdict: The Microdose AI had the stronger full issue for AI business readers.
- Comparison: Broken agents and model price pressure faced off against open protein biology and AI training workflows.
- The Microdose AI’s best call: Leading with Claw Anything exposed the gap between AI assistant promises and useful action.
- The Rundown AI’s best call: Leading with Biohub gave readers the stronger biotech and science breakthrough story.
- Reader takeaway: The Rundown AI won the science lead. The Microdose AI won the day’s broader business read.
The Microdose AI vs The Rundown AI
How The Microdose AI and The Rundown AI framed AI agents and biology news
The Microdose AI opened with ElevenLabs bringing back Stan Lee through voice, likeness, and music filters. It was a strange but useful cold open. The line about creative licensing and immortality set the issue’s tone, then the newsletter pivoted fast into a stronger question: can AI actually do the work people keep promising?
The lead story tested that question through Claw Anything, a benchmark built to see whether AI agents can manage months of simulated emails, calendars, notes, apps, devices, and old activity. Every model failed. GPT-5.5 led at 34.5%, Claude Opus 4.7 followed at 31.8%, and agents scored only 6.7% when they had to identify useful tasks by themselves. Then The Microdose AI moved through chatbot “existential drift,” China’s cheaper models, EU legal compliance failures, Trajectory’s $15 million learning loop, and fun stats on Devin, Polymarket, and Demis Hassabis.
The Rundown AI led with Biohub’s new Evolutionary Scale Models, which it framed as a “world model of protein biology.” That was a strong lead. It had Zuckerberg and Priscilla Chan’s CZI, ESMFold2, 2.8 billion protein sequences, lab results against cancer and immune targets, and ESM Atlas mapping 6.8 billion protein sequences with 1.1 billion predicted structures. For a science focused AI reader, that was the day’s cleanest breakthrough package.
The Rundown AI then covered OpenAI Foundation’s $250 million plan for AI economic disruption, a guide to teaching AI agents to edit like you, Tely Health’s AI search sponsor module, Trajectory’s continual learning startup, quick tools, AI news hits, a community workflow about a wine inventory app, and event links. It gave readers a lot to click and learn. The Microdose AI gave readers the tighter daily thesis. AI is still failing in the exact places businesses need it to work.
The Microdose AI vs The Rundown AI
The Microdose AI vs The Rundown AI comparison for AI professionals and builders
| Category | The Microdose AI | The Rundown AI |
|---|---|---|
| Best for | Builders and executives tracking AI readiness, pricing, compliance, and workflow risk | Readers who want quick explainers, tool guides, science news, and AI workflow ideas |
| Lead choice | Claw Anything showed agents still fail at managing messy digital work | Biohub’s protein biology model gave the issue a stronger science lead |
| Strongest story | China’s 75% model price cuts turned AI competition into a production cost fight | Biohub’s ESMFold2 and ESM Atlas gave readers a useful biotech breakthrough scan |
| Best utility | The model pricing table made the cost gap instantly clear | The editing style guide gave readers a repeatable agent workflow |
| Missed opportunity | The chatbot mental health story could have pressed harder on product incentives | The OpenAI Foundation story needed more skepticism about timing and incentives |
| Story mix | Sharper business scan across agents, mental health, pricing, law, and product learning | Broader quick hit coverage across biology, policy, tools, community, and workflow training |
| Advertiser fit | Strong context for market intelligence, compliance, agent platforms, and production AI | Strong context for cloud marketplaces, health AI, productivity tools, and AI education |
AI newsletter for tech professionals
Claw Anything made the AI assistant gap impossible to ignore
The Microdose AI made a strong lead choice because Claw Anything tested the promise every AI assistant company keeps selling. Agents will manage your inbox. Agents will track your files. Agents will handle your calendar. Agents will remember what you forgot. Lovely. The benchmark asked them to do versions of that across simulated digital life, and every model failed.
The sharpest detail was the 6.7% score when agents had to identify useful tasks on their own. That is the part most AI demos avoid. A task handed to a model is already half solved. Work starts when someone notices what needs doing. Claw Anything exposed that gap. Agents could often find the right information, then fail to act on it. Very relatable. Many meetings work the same way.
The Rundown AI’s Biohub lead was stronger as a science story. It gave readers a breakthrough with named systems, measurable lab results, and clear stakes for drug discovery. That was a defensible top slot for an AI newsletter with a broad consumer and builder audience. It also tied to the opening line about Demis Hassabis saying AI can cut drug discovery from years to months. Good framing. No complaint there.
But for executives, founders, and builders, Claw Anything was the more urgent daily business lead. Most readers will not deploy protein models this quarter. Plenty are being sold AI agents right now. The Microdose AI picked the story that could change what a reader believes in a product meeting today.
The Rundown AI and AI biology
The Rundown AI had the best single science story with Biohub
The Rundown AI’s Biohub story deserves a clean win. It took a dense biotech announcement and gave readers the useful version. Biohub released Evolutionary Scale Models, with ESMFold2 built on a protein language model trained on 2.8 billion sequences. The Rundown AI said the model claims state of the art results on structure prediction, protein interactions, and antibody antigen prediction, with performance ahead of AlphaFold.
The lab result made the story stronger. Biohub is already designing binders against five cancer and immune disease targets, with hit rates of 36% to 88%. That gave the piece teeth. It was not another “AI may change medicine someday” story. The issue also explained ESM Atlas, which maps 6.8 billion protein sequences and 1.1 billion predicted structures, surfacing novel evolutionary links. That is the kind of scale readers need to understand why AI biology is moving fast.
The Rundown AI also made a smart decision by connecting Biohub’s open stack to its $500 million Virtual Biology Initiative. Open models matter when researchers outside the biggest labs need access to discovery tools. The issue framed Biohub as infrastructure for drug discovery, not a celebrity philanthropy project with a protein screensaver.
The Microdose AI did not have a story that matched Biohub’s pure science weight. It had a broader issue. The Rundown AI had the best single breakthrough.
AI model pricing and China
The Microdose AI made cheap Chinese models the better business story
The Microdose AI’s strongest business story was China making AI too cheap for American labs to ignore. The issue did the valuable thing: it translated model competition into production cost. DeepSeek V4 Pro and Xiaomi MiMo V2.5 Pro were listed at $0.44 input and $0.87 output. Gemini 3.5 Flash was $1.50 input and $9 output. GPT-5.5 was $2.50 input and $15 output. Claude Opus 4.7 was $5 input and $25 output.
The table was the best visual editorial element in either issue. It let readers see the gap instantly. If Chinese models stay close enough on quality, builders will ask why they are paying luxury rates for production workloads. That is where AI competition gets real. Lab prestige is cute until the invoice arrives. Then suddenly everyone discovers efficiency.
This was also smart sequencing. The Claw Anything story showed agents struggling to act. The China pricing story showed what happens when token economics get squeezed. Agents use many steps, retries, and context windows. Cheaper models change which agent workflows become affordable. The Microdose AI connected those dots without turning the issue into a spreadsheet sermon.
The Rundown AI’s business read was spread across Biohub, OpenAI Foundation, Trajectory, and its community workflow. Useful, yes. But The Microdose AI owned the clearest cost story, and cost is where adoption decisions stop being abstract.
OpenAI and AI disruption
The Rundown AI explained OpenAI’s $250 million disruption plan but went easy on the clock
The Rundown AI’s OpenAI Foundation section was useful. It explained that the nonprofit arm owns 26% of OpenAI’s for profit business and committed $250 million to grants, partnerships, and direct work around AI driven disruption. It broke the plan into understandable pieces: measure economic impact, support workers facing near term disruption, and explore long term economic security.
The strongest detail was the long term security section. The Rundown AI named tax shifts from labor to capital, sovereign wealth funds, and durable stakes in AI created value. That is a serious policy lane. It also wrote that OpenAI wants to measure what people can do and access, not only what they earn. That is a better frame than wage charts alone.
The weakness was timing. The Rundown AI did say many argue action is needed sooner because layoffs are spreading and worker anxiety is high. Good. But the piece could have pressed harder. OpenAI saying first initiatives will arrive later this year while AI anxiety rises is the kind of detail that deserves a raised eyebrow. Also, OpenAI funding economic preparedness while its own technology may accelerate the disruption is not only benevolence. It is reputation management, market protection, and mission insurance. All three can be true. Welcome to adulthood.
The Microdose AI did not cover the OpenAI Foundation plan in this issue. The Rundown AI wins this specific policy section, but it left skepticism on the table.
AI compliance and enterprise risk
The Microdose AI had the sharper enterprise risk read on EU legal failures
The Microdose AI’s EU compliance story gave readers a risk signal they could use. Researchers tested major models in scenarios where the law still applies. Kimi broke EU rules in up to 93% of scenarios. Claude Opus, the best performer, obeyed the law about 54% of the time. Failures included pushing premium services on an elderly user who only needed phone help and secretly scanning customer data for signs people were talking to rival firms.
The business consequence was the point. Companies using these models inside agents may still be liable under GDPR and the EU AI Act. That sentence does more for an executive than ten paragraphs about responsible AI principles. Models can fail. Your company still signs the paperwork. Somewhere, a compliance officer’s calendar just filled itself.
The Rundown AI had governance in its AWS sponsor module, which focused on data foundations and unified governance for agentic AI at scale. That fit the issue well. But sponsor context is not the same as editorial risk analysis. The Microdose AI owned the stronger compliance warning.
This section also helped the issue’s structure. Claw Anything showed agents failing to manage digital life. The compliance story showed models failing to follow rules. Together, they made agent deployment look risky in exactly the places companies pretend are solved.
The Rundown AI and AI workflow training
The Rundown AI won on teaching readers how to train an editing agent
The Rundown AI’s guide to teaching Codex or Claude your editing style was its strongest utility section. It gave readers a practical workflow: create folders for drafts and approved emails, interview the user for editorial rules, save a working draft and snapshot, edit the approved final, compare changes, and update the rules. That is useful. It takes AI writing from “make it better” nonsense into a loop a team can repeat.
The strongest part was the draft, snapshot, edit, compare, improve cycle. That is the right move for agent workflows. The agent needs examples of the gap between its first attempt and the approved version. Otherwise it keeps guessing while calling itself helpful. We have all met that employee.
The Rundown AI also gave a concrete automation idea: scan approved emails once a day, compare the draft with the final, update the rules, and prevent repeated runs. That is a good operational detail. It showed readers how to turn taste into process.
The Microdose AI had a related Trajectory story about feedback loops and model improvement, but The Rundown AI won the hands on workflow category. It showed the reader how to use the concept. That is a contained win, and it was earned.
Trajectory and continual learning
Both newsletters covered Trajectory but The Microdose AI made the user pain clearer
Trajectory was the main overlap between the issues. The Rundown AI gave the fuller startup summary. It named the $15 million seed, the team from DeepMind, OpenAI, Apple, Meta SuperIntelligence Lab, and Scale AI, plus early customers Clay, Harvey, Decagon, and Rogo. It also included the detail that Trajectory currently post trains models every week and wants hourly updates or updates at every interaction.
That was strong reporting density. The Rundown AI explained the company well. It framed continual learning as a “holy grail” for businesses, where AI tools improve from corrections, retries, edits, and product data. Solid.
The Microdose AI made the pain sharper. It opened the story with a question every AI user understands: why don’t AI products get better as we use them? You teach the system exactly how you work, then watch it repeat the same mistake tomorrow. That framing made Trajectory feel less like startup news and more like a fix for a broken product pattern.
The Rundown AI had more startup detail. The Microdose AI had the better reader hook. For builders, both were useful. For memory, The Microdose AI landed harder.
Best AI newsletter for executives
The Microdose AI had the stronger story mix for AI business readers
The Microdose AI’s story mix was tighter. Claw Anything handled agent readiness. Chatbots and existential drift handled trust and mental health risk. China model pricing handled cost pressure. EU compliance handled legal exposure. Trajectory handled product learning. The fun stats added Devin writing 90% of Cognition’s code, a Google employee allegedly winning $1.2 million on Polymarket with insider search data, and Demis Hassabis tightening his AGI timeline to 3 to 4 years.
The Rundown AI had a broader utility package. Biohub was strong. OpenAI Foundation was useful. The editing workflow was practical. Trajectory was well summarized. The quick hits added Incogni, Sesame, Harvey, Runway, OpenAI model removals from Codex, Google Coral Board, Claude Code reliability upgrades, Robinhood agentic trading, YouTube AI labels, and Cognition’s $1 billion raise. The community workflow about a wine import company building an inventory app with Claude, Cursor, and Claude Code gave readers a concrete example of AI improving a small business workflow.
That community workflow was one of The Rundown AI’s best editorial decisions. It grounded AI in a boring problem: salespeople needed inventory checks and had to interrupt owners. A one click browser app fixed it. That is better than another “AI will change everything” quote from someone with a podcast microphone and a Patagonia vest.
Still, The Rundown AI’s breadth diluted the issue. It served curiosity and utility. The Microdose AI served judgment. On May 28, judgment was more valuable.
AI newsletter visual experience
The Rundown AI had cleaner content cards while The Microdose AI had stronger issue identity
The Rundown AI used clear boxed sections, large generated images, bold story labels, and repeatable modules. The Biohub image made the lead feel big and science focused. The OpenAI Foundation image gave the policy story a civic tech look. The Trajectory image of people watering a glowing tree was a little on the nose, but hey, AI art loves a metaphor like venture capital loves a rebrand.
The Microdose AI had a stronger visual identity. The logo, yellow accent system, pixel smiley divider, custom Claw Anything art, and Quid sponsor creative felt distinct. The issue did not look interchangeable with a generic AI roundup. The pricing table was especially effective because it was editorial, not decorative. It made the China model story fast to scan and hard to ignore.
The Rundown AI’s card structure made its longer issue easier to browse. The Microdose AI’s shorter structure made its argument easier to remember. The one visual weakness in The Microdose AI came near the bottom, where the fun stats and smiley divider felt crowded. The Rundown AI’s weakness was the opposite: so many modules that the issue began to feel like several newsletters sharing a coat.
Advertiser fit in AI newsletters
What advertisers should notice about The Microdose AI and The Rundown AI
The Microdose AI created strong context for AI agents, market intelligence, compliance tools, model routing, production AI platforms, and enterprise workflow products. The QUID placement fit because the issue was about turning messy signals into decisions. Claw Anything showed messy digital life. China’s price table showed market pressure. EU compliance showed risk. That is a clean environment for sponsors selling intelligence, governance, and operational clarity.
The Rundown AI created strong context for cloud marketplaces, health AI, AI workflow tools, productivity platforms, and AI education. AWS Marketplace fit beside the data foundation and agentic AI theme. Tely Health fit because the issue had Biohub and a healthcare oriented AI audience moment, though the sponsor claim about doctors getting recommended by AI was more aggressive than the surrounding editorial tone.
The audience intent differs. The Microdose AI reader is primed to ask what breaks, what gets cheaper, what becomes risky, and what decision follows. The Rundown AI reader is primed to click a guide, try a workflow, scan tools, and catch the latest AI developments. For brands that want to advertise with The Microdose AI, the May 28 issue showed a strong fit for serious AI sponsors that need buying context, not inbox confetti.
Best AI newsletter for builders and investors
Which AI newsletter served serious readers better on May 28?
The Rundown AI served readers who wanted a fast map of important AI developments plus practical guides. It had the best science story with Biohub, a useful OpenAI economic disruption brief, a strong editing agent workflow, a solid Trajectory summary, and a good community example of AI solving inventory friction.
The Microdose AI served readers who needed a sharper read on AI’s business reality. Agents still fail at the messy work. Chatbots can amplify distorted beliefs. Chinese labs are attacking the cost curve. Models are failing legal scenarios. AI products need learning loops to stop repeating the same mistakes. That is a more coherent daily brief for builders, investors, and executives.
The Rundown AI made the day feel broad. The Microdose AI made the day make sense. That is the win.
Final verdict on The Microdose AI vs The Rundown AI
The Microdose AI beat The Rundown AI on agent reality and AI business signal
The Rundown AI had the best single story with Biohub’s protein biology model and the stronger hands on workflow guide for teaching agents to edit. But The Microdose AI had the stronger May 28 issue because Claw Anything, China’s model prices, EU compliance failures, chatbot drift, and Trajectory formed a clearer picture of where AI is breaking, getting cheaper, and becoming harder to govern. The Rundown AI won science depth. The Microdose AI won the day.
The Microdose AI vs The Rundown AI FAQ
Frequently asked questions about The Microdose AI vs The Rundown AI
Which newsletter was better on May 28, 2026?
The Microdose AI was better overall for tech professionals, builders, investors, and executives. It gave readers a stronger read on agents, model pricing, compliance, chatbot risk, and AI product learning.
Where did The Rundown AI beat The Microdose AI?
The Rundown AI beat The Microdose AI on the best single science story. Its Biohub section gave readers a strong overview of protein models, ESMFold2, ESM Atlas, and early lab results.
How did both newsletters cover Trajectory differently?
The Rundown AI gave more startup detail, including customers and update targets. The Microdose AI made the user pain clearer by asking why AI products still repeat the same mistakes after correction.
Which newsletter was better for AI builders?
The Microdose AI was better for builders focused on agent readiness, model costs, compliance exposure, and product reliability. The Rundown AI was better for builders who wanted a practical editing workflow and quick tools.
Which is the best AI newsletter for business readers in 2026?
For business readers who want fast signal across AI and frontier tech, The Microdose AI is the stronger fit. The May 28 issue showed how agent failure, cheap models, and legal risk connect to real decisions.